CTOs on the Move

Axovant

www.axovant.com

 
Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. We aspire to lead the way into a new era of progress to protect the fullness of life for people living with neurologic conditions. We see the potential of compelling therapeutic pathways and set our sights high on creating life-changing advancement for millions of people affected by neurologic disorders.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.axovant.com
  • 11 Times Square 33rd Floor
    New York, NY USA 10036
  • Phone: 833.296.8268

Executives

Name Title Contact Details
John Wright
Chief Technology Officer Profile

Similar Companies

Wolfe Laboratories

Wolfe Laboratories is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Proteomics

Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

Woodcock Washburn

Woodcock Washburn is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Temporary Technical Services Inc

Temporary Technical Services Inc is a Jackson, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galecto

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.